Suppr超能文献

双重抑制内皮细胞 miR-92a-3p 和 miR-489-3p 可减轻肾损伤相关的动脉粥样硬化。

Dual inhibition of endothelial miR-92a-3p and miR-489-3p reduces renal injury-associated atherosclerosis.

机构信息

Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA.

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.

出版信息

Atherosclerosis. 2019 Mar;282:121-131. doi: 10.1016/j.atherosclerosis.2019.01.023. Epub 2019 Jan 30.

Abstract

BACKGROUND AND AIMS

Cardiovascular disease (CVD) is the leading cause of death in chronic kidney disease (CKD) patients, however, the underlying mechanisms that link CKD and CVD are not fully understood and limited treatment options exist in this high-risk population. microRNAs (miRNA) are critical regulators of gene expression for many biological processes in atherosclerosis, including endothelial dysfunction and inflammation. We hypothesized that renal injury-induced endothelial miRNAs promote atherosclerosis. Here, we demonstrate that dual inhibition of endothelial miRNAs inhibits atherosclerosis in the setting of renal injury.

METHODS

Aortic endothelial miRNAs were analyzed in apolipoprotein E-deficient (Apoe) mice with renal damage (5/6 nephrectomy, 5/6Nx) by real-time PCR. Endothelial miR-92a-3p and miR-489-3p were inhibited by locked-nucleic acid (LNA) miRNA inhibitors complexed to HDL.

RESULTS

Renal injury significantly increased endothelial miR-92a-3p levels in Apoe;5/6Nx mice. Dual inhibition of miR-92a-3p and miR-489-3p in Apoe;5/6Nx with a single injection of HDL + LNA inhibitors significantly reduced atherosclerotic lesion area by 28.6% compared to HDL + LNA scramble (LNA-Scr) controls. To examine the impact of dual LNA treatment on aortic endothelial gene expression, total RNA sequencing was completed, and multiple putative target genes and pathways were identified to be significantly altered, including the STAT3 immune response pathway. Among the differentially expressed genes, Tgfb2 and Fam220a were identified as putative targets of miR-489-3p and miR-92a-3p, respectively. Both Tgfb2 and Fam220a were significantly increased in aortic endothelium after miRNA inhibition in vivo compared to HDL + LNA-Scr controls. Furthermore, Tgfb2 and Fam220a were validated with gene reporter assays as direct targets of miR-489-3p and miR-92a-3p, respectively. In human coronary artery endothelial cells, over-expression and inhibition of miR-92a-3p decreased and increased FAM220A expression, respectively. Moreover, miR-92a-3p overexpression increased STAT3 phosphorylation, likely through direct regulation of FAM220A, a negative regulator of STAT3 phosphorylation.

CONCLUSIONS

These results support endothelial miRNAs as therapeutic targets and dual miRNA inhibition as viable strategy to reduce CKD-associated atherosclerosis.

摘要

背景与目的

心血管疾病(CVD)是慢性肾脏病(CKD)患者死亡的主要原因,但导致 CKD 和 CVD 的潜在机制尚未完全阐明,并且在这一高危人群中治疗选择有限。microRNAs(miRNA)是动脉粥样硬化中许多生物学过程的关键基因表达调控因子,包括内皮功能障碍和炎症。我们假设肾损伤诱导的内皮 miRNA 促进动脉粥样硬化。在这里,我们证明了内皮 miRNA 的双重抑制可抑制肾损伤情况下的动脉粥样硬化。

方法

通过实时 PCR 分析载脂蛋白 E 缺陷(Apoe)小鼠伴肾损伤(5/6 肾切除术,5/6Nx)的主动脉内皮 miRNA。用与高密度脂蛋白(HDL)结合的锁核酸(LNA)miRNA 抑制剂抑制内皮 miR-92a-3p 和 miR-489-3p。

结果

肾损伤显著增加了 Apoe;5/6Nx 小鼠内皮 miR-92a-3p 的水平。用 HDL+LNA 抑制剂单次注射对 Apoe;5/6Nx 的 miR-92a-3p 和 miR-489-3p 的双重抑制与 HDL+LNA 对照(LNA-Scr)相比,显著减少了 28.6%的动脉粥样硬化病变面积。为了检查双重 LNA 治疗对主动脉内皮基因表达的影响,完成了总 RNA 测序,并确定了多个假定的靶基因和途径发生了显著改变,包括 STAT3 免疫反应途径。在差异表达的基因中,Tgfb2 和 Fam220a 分别被鉴定为 miR-489-3p 和 miR-92a-3p 的假定靶基因。与 HDL+LNA-Scr 对照组相比,体内 miRNA 抑制后,Tgfb2 和 Fam220a 在主动脉内皮中均显著增加。此外,基因报告实验验证了 Tgfb2 和 Fam220a 分别是 miR-489-3p 和 miR-92a-3p 的直接靶基因。在人冠状动脉内皮细胞中,miR-92a-3p 的过表达和抑制分别降低和增加了 FAM220A 的表达。此外,miR-92a-3p 的过表达增加了 STAT3 磷酸化,可能通过 FAM220A 的直接调节,FAM220A 是 STAT3 磷酸化的负调节因子。

结论

这些结果支持内皮 miRNA 作为治疗靶点,以及双重 miRNA 抑制作为减少 CKD 相关动脉粥样硬化的可行策略。

相似文献

引用本文的文献

2
Current Understanding of piRNA in Cardiovascular Diseases.当前对心血管疾病中piRNA的认识。
Front Mol Med. 2022 Jan 12;1:791931. doi: 10.3389/fmmed.2021.791931. eCollection 2021.
6
Leukocyte-endothelial interaction in CKD.慢性肾脏病中的白细胞-内皮细胞相互作用
Clin Kidney J. 2023 Jun 8;16(11):1845-1860. doi: 10.1093/ckj/sfad135. eCollection 2023 Nov.
7
MicroRNAs in cardiovascular diseases.心血管疾病中的微小RNA
Med Rev (2021). 2022 Apr 26;2(2):140-168. doi: 10.1515/mr-2021-0001. eCollection 2022 Apr.

本文引用的文献

5
MicroRNA-92a Mediates Endothelial Dysfunction in CKD.微小RNA-92a介导慢性肾脏病中的内皮功能障碍。
J Am Soc Nephrol. 2017 Nov;28(11):3251-3261. doi: 10.1681/ASN.2016111215. Epub 2017 Jul 10.
8
FDA-Approved Oligonucleotide Therapies in 2017.2017年美国食品药品监督管理局批准的寡核苷酸疗法
Mol Ther. 2017 May 3;25(5):1069-1075. doi: 10.1016/j.ymthe.2017.03.023. Epub 2017 Mar 31.
9
MicroRNAs in the Pathobiology and Therapy of Atherosclerosis.微小RNA在动脉粥样硬化的病理生物学及治疗中的作用
Can J Cardiol. 2017 Mar;33(3):313-324. doi: 10.1016/j.cjca.2017.01.001. Epub 2017 Jan 5.
10
HDL and microRNA therapeutics in cardiovascular disease.高密度脂蛋白与微小RNA疗法在心血管疾病中的应用
Pharmacol Ther. 2016 Dec;168:43-52. doi: 10.1016/j.pharmthera.2016.09.001. Epub 2016 Sep 3.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验